FACIT congratulates portfolio company KA Imaging on significant clinical development milestone.
![](http://facit-staging.gotenzing.com/wp-content/uploads/2021/11/FACIT20features20KA20Imaging.jpg)
November 12, 2018 – We are pleased to offer our congratulations to KA Imaging, a recent Prospects Fund recipient, on the initiation of their first-in-human trial investigating the use of their high-resolution multi-energy digital x-ray in patients with lung nodules. The pilot study is in partnership with Grand River Hospital of Kitchener, Ontario.
Read the news release here.
About KA Imaging:
KA Imaging of Kitchener, Ontario is developing a digital panel that improves the quality and accuracy of chest X-rays by creating multi-spectral (sometimes called dual-energy) X-ray images. KA Imaging’s dual-energy chest X-ray panel will use different X-ray energies to highlight different structures, such as bone versus soft tissue, without motion artifacts. This promises better detection and visualization of lung tumours than conventional X-ray imaging, and at much lower radiation doses than CT scans which are known to increase cancer risk. KA Imaging’s chest X-ray panel is designed to retrofit into existing systems, thereby reducing cost and expanding the availability of dual-energy imaging for lung cancer screening.
![](https://facit.ca/wp-content/uploads/2022/07/Portfolio.jpg)
PORTFOLIO
FACIT actively manages our diverse portfolio of Ontario oncology assets (including therapeutics, imaging, diagnostics, and technology platforms) that span all stages of commercialization, from proof-of-concept to clinical development.
![](https://facit.ca/wp-content/uploads/2022/07/Funds.jpg)
FUNDS
With critical seed funding, FACIT makes it possible for Ontario’s best cancer research discoveries to compete globally and reach patients.